A leading radiopharmaceutical tech startup, Nucleus RadioPharma, has secured additional capital in a Series A funding round led by AstraZeneca to make targeted theranostics and radiotherapies more accessible for personalized cancer therapy worldwide.
Through the latest funding round, AstraZeneca joined the list of existing investors at Nucleus RadioPharma, including Mayo Clinic, GE Healthcare, Eclipse Ventures, the University of Missouri, Echo Global Granger Management Mercy Health, and Fox Chase Cancer Center.
According to the company’s announcement on Wednesday, June 5, 2024, this financing round will help expand the development, supply, and commercial manufacturing capabilities of Theranostic radiopharmaceuticals, paving the way for future large-scale manufacturing to boost global accessibility of life-saving treatments.
Theranostics— the Future of Personalized Cancer Therapy
Theranostics is a technique that combines diagnostics and therapeutics for Personalized cancer therapy. Radiotracers target and bind to specific types and forms of cancer cells. Using low doses of radiotracers, physicians can visualize tumors and guide targeted therapy, while high-dose radiotracers kill the identified cancer or tumor cells with minimal impact on surrounding healthy tissues.
Due to its precision, the Theranostics technique shows better results with reduced side effects in cancer patients compared to traditional treatment techniques, making it a promising option for treating metastatic cancers such as prostate cancer, lymphoma, and tumors.
Tyrell Rivers, PhD, Executive Director of Corporate Ventures at AstraZeneca, will join Nucleus RadioPharma’s board as part of the financing deal.
